Member Info for RayPointer

or a skateboard :-)

Interesting Bermuda
An easy walk between the 2 labs with perhaps a coffee shop in between.

It looks like Scancell have found that new lab they were looking for.

"Scancell’s existing laboratories are based in Nottingham. However, the Company is expanding into new laboratory facilities on the Oxford Science Park, where activities will focus on translational research, support for the Company’s clinical trial activities, and formulation and analytical development activities for its novel products. The positions currently available will be based at the Oxford Science Park and will support Scancell’s clinical trials by performing immunological assays in accordance with the clinical study protocols"

C11, is a 12% rise enough to retire on :-)

Yes, that was her thinking. Presumably take some blood from a patient vaccinated with modi1 and repeat the process to create the viral vector.

To me the important thing about the modi1 trial is whether or not the manufacture is now complete and looking good. The last we heard was that the 3 conjugates had been manufactured and what remained was combining the 3.

He actually said expect more deals in the Eastern Limb

Yes, to spend all that money would have required quite a lifestyle :-)

https://www.lse.co.uk/rns/SCLP/confirmation-of-gbp285-million-payment-dljnca70edccktl.html

Is this what you were thinking about AB?

Scancell did do a commercial deal some time ago with an Australian company on a number of mAbs prior to running the SCIB1 trial. This was not part of their current platforms.

Other bodies have been allowed to develop Immunobody vaccines e.g. Nottingham Trent Uni. but, as far as I know, none of these have actually resulted in clinical trials.
SCIB1 is the only Immunobody product for which a trial has been conducted.

AB
None so far.
In fact none have yet reached the phase 3 stage.

https://www.acsh.org/news/2020/06/11/clinical-trial-success-rates-phase-and-therapeutic-area-14845

This article clearly indicates the difficulty of reaching the approval stage for cancer drugs.
It also indicates that only about a third of cancer drugs that pass phase 1 then progress to phase 3.

So in most products Scancell would probably be looking to run phases 1 and 2 and then, if the results warrant it, seek a partner to run phase 3. All their cancer trials past and planned are following this pattern so far.

Covidity may be the exception to this in running only phase 1 and then seeking a partner.

Lindy will have the best knowledge and experience to judge the chance of success and the degree of success.
We can only speculate.

It's pleasing to see that the research branch of JLP is not resting on its laurels. Work is going on to improve the current processes. This perhaps augurs well for JLP retaining a lead in the processing of waste materials.

Wild
That's a very interesting article.
The balance between the brilliance of an individual and being able to modularise the required tasks and assign to the relevant experts in that particular field sometimes via collaborations.
That's quite a mouthful :-)

But to quote of a few examples

ISA pharmaceuticals collaboration to provide an adjuvant for Moditope
Prof Dixon's team to provide a delivery system for Covidity
Adrian Parry hired to provide expertise in manufacture and Moditope in particular
Dare I say, the GC team with experts in a range of disciplines
Cliff with his tea making ability :-)

It seems Scancell are also good at providing that balance

Particularly relevant to Scancell is the following paragraph

"Vaccine that trains body to fight disease
Vaccines are already widely used to prevent infections – notably Covid. Could they also be created to treat cancer? The answer may be yes, if the promising results of an early-stage ovarian cancer trial are to be believed. All vaccines work by training the body’s immune system to recognise and fight invading pathogens. This is usually done by introducing a harmless fragment of the pathogen, which the immune system reacts to but which doesn’t cause illness.

A newly developed ovarian cancer vaccine works in the same way – it contains DNA fragments found in ovarian tumour cells. By injecting these, the immune system ‘switches on’ and attacks real tumour cells. In the trial, the jabs were given once a month for a year after standard surgery or chemotherapy. The results show that in 45 patients, the vaccine halted progression of their cancer for up to ten months.

Dr Arkenau said: ‘Vaccines will be the next big development in fighting cancer and will eventually make the immunotherapies we’re talking about now irrelevant. It appears as though this particular vaccine works very well in patients without the BRCA mutation. The next step for the scientists involved will be a larger trial with more participants.’"

And then also a large part of the article is about checkpoint inhibitors.
Anybody know of a trial that uses a CI and DNA fragments :-)

Leon on great form as usual.

wikipedia adds more context to this latest piece of news.

https://en.wikipedia.org/wiki/Bushveld_Igneous_Complex

WTP, I guess that certain types of technology are in vogue at a given time.
I suspect CAR-T is in that category. Didn't Burble once say that his colleagues talk a lot about CAR-T.

Cancer vaccines of the type Lindy is keen on have been discredited in the past with a number of failures.
So, I would guess that big pharma turned away from cancer vaccines but may now be slowly beginning to be interested again.

So, successful trials with SCIB1 and Modi1 may revive the interest in a big way.
Of course, Covidity is the joker in the pack that may put Scancell's science firmly in the limelight.

Obiwan may the force be with you :-)